B+
Bull case
30%
Probability
Target price
$49.00
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
HRMY
Harmony BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
WAKIX growth and patient gains support the reiterated 2026 revenue range, while favorable BP-205 data and pitolisant GR progress could broaden the franchise [#SEC-8K-2026-08-04].
Posture
Constructive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-26.
What can break
BP-205 data may disappoint on safety, tolerability, or development prospects; efficacy is not yet established [#SEC-8K-2026-08-04].
Momentum
64
Value
70
Sentiment
60
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $39.00 · Bull $49.00 · Bear $26.00Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $48.25
Why
Momentum64 · Δ7d -5.4
Value70 · Δ7d +0.0
Sentiment60 · Δ7d +3.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-26.
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • BP-205 data may disappoint on safety, tolerability, or development prospects; efficacy is not yet established [#SEC-8K-2026-08-04].
- • CEO succession could disrupt commercial or pipeline execution despite management's stated expectation of unchanged milestone timing [#8-K-2026-10-13].
- • Revenue remains concentrated in WAKIX, the pipeline faces clinical and regulatory uncertainty, and the CEO transition adds execution risk [#SEC-8K-2026-08-04] [#8-K-2026-10-13].
Catalyst clock
2026-12-31
BP-205 multiple-ascending-dose data
Lead driver: Value · See fundamentals
Momentum
64
8% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
-12.4
Value
70
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.3
Sentiment
60
45% active weight
Current posture
7d trendImproving
Δ7d
+3.5
Δ21d
+4.1
Why this grade
Composite grade A. Momentum 64.3 / Value 69.7 / Sentiment 60.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$26.00
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.14B
Beta
0.84
Shares Out
58.24M
P/E (TTM)
11.6
P/S (TTM)
2.56
P/FCF (TTM)
7.13
Rev YoY
+30.3%
EPS YoY
+88.6%
Gross Margin
+72.9%
Op Margin
+24.0%
Net Debt
-$540.27M
Current Ratio
3.48
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data